Abstract Background Favipiravir and Molnupiravir, orally available antivirals, have been
reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently …

Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in
clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we use a …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the
globe after its emergence in Wuhan in December 2019. With no specific therapeutic and …

There is currently an outbreak of respiratory disease caused by a novel coronavirus. The
virus has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and …

ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …

There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir
and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …